2025医保药品目录公布，新增114种药品

Core Viewpoint - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative Class I drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [1][5]. Group 1 - The 2025 National Medical Insurance Drug List includes drugs that fill gaps in basic medical insurance coverage, such as treatments for triple-negative breast cancer, pancreatic cancer, and lung cancer [5]. - The list also incorporates medications for rare diseases like Langerhans cell histiocytosis and thalassemia, as well as chronic diseases such as diabetes and autoimmune diseases [5]. - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines, enhancing coverage in key areas like cancer, chronic diseases, mental health, rare diseases, and pediatric medications [5]. Group 2 - The first version of the commercial insurance innovative drug list includes 19 drugs, featuring CAR-T therapies for cancer treatment, medications for neuroblastoma and Gaucher disease, and treatments for Alzheimer's disease [5].